LASERSIGHT ANNOUNCES JOINT VENTURE WITH BECTON DICKINSON AND
                              FIRST QUARTER RESULTS

Winter Park, FL. (May 17, 1999) - LaserSight  Incorporated (NASDAQ:  LASE) today
announced an alliance with Becton Dickinson Ophthalmic Systems, a Worldwide
Business of Becton Dickinson and Company (NYSE:BDX). The joint venture brings
together the products and expertise of two companies in the field of
ophthalmology focused particularly on refractive surgery.

As part of the joint venture Becton Dickinson  Ophthalmic Systems and LaserSight
have entered into an exclusive arrangement to develop, manufacture and
distribute keratome blades for refractive surgery. Additionally, the partnership
will further expand the LaserSight product line by manufacturing cannulas,
custom kits for refractive surgery and other laser vision correction related
accessories. LaserSight will access Becton Dickinson's sales and distribution
capabilities around the world to accelerate the launch of its products and meet
the market's growing demand.
                                                        
Becton Dickinson  Ophthalmic  Systems is the worldwide leader in the manufacture
and sales of surgical blades and ophthalmic cannula under the Beaver(R) and
Visitec(R) brands. The products of Becton Dickinson Ophthalmic Systems and
LaserSight enjoy a reputation for excellence and innovation. This combination
strategically positions the two companies to gain market share more effectively
and efficiently within the rapidly growing refractive surgery market.

Separately,  the Company announced financial results for the first quarter ended
March 31, 1999. Revenues related to sales of laser systems, upgrades and part
sales increased over the quarter ended December 31, 1998 and the quarter ended
March 31, 1998.

<PAGE>

Revenues for the first quarter increased  approximately 17% to $4.9 million from
$4.2 million in the first quarter of 1998. The Company reported a net loss of
$3.3 million, or $0.25 per share, compared to a net loss of $2.0 million
reported for the first quarter of 1998 before the additional $1.1 million loss
for that quarter of 1998, reflecting the effects of premiums, accretion and
conversion discounts on the redemption of Series B Preferred Stock. The loss per
share in the first quarter of 1998 was $0.30. The average common shares
outstanding were 13,418,000 during the first quarter of 1999 compared to
10,318,000 in the first quarter of 1998.

Compared to the fourth quarter of 1998,  revenues  increased  approximately  48%
from $3.3 million. Additionally, the net loss for the first quarter of 1999
narrowed significantly compared to the net loss of $6.0 million, or $0.46 per
share reported in the fourth quarter of 1998. The relative improvement during
the first quarter of 1999 primarily resulted from the increased revenues and
corresponding improved margin as well as a reduction of approximately $1.0
million in total operating expenses.

During the three  months  ended March 31, 1999 the  Company  sold 13  refractive
laser systems to international customers compared to 8 systems during the fourth
quarter of 1998. In addition to an increase in average selling price during the
quarter, the terms of sale improved as a result of the markets the Company has
gained access to through the CE Mark approval previously announced.
                                                     
Michael R.  Farris,  Chief  Executive  Officer,  commented,  "We  continue to be
pleased with the progress we are making with our laser system and keratome
products. Our strategic alliance with Becton Dickinson, a well-respected and
resourceful organization, strenghthens LaserSight's position to compete with
other broad line companies while allowing us to lead the industry with focused
innovation. Focused on clinical quality and technological innovation, the
partnership will increase LaserSight's ability to meet customer demand for its
products, further establish its brand name recognition for quality and
innovation, and increase market share in a rapidly growing industry."

<PAGE>

LaserSight   Incorporated   provides  quality  technology  solutions  for  laser
refractive surgery and other innovative applications, mainly in the vision
correction industry. The Company sells its products in more than 30 countries.
In the United States, LaserSight's refractive scanning laser system has a
pending pre-market approval application with the U.S. Food and Drug
Administration and is not yet commercially available in this market.

This press release contains  forward-looking  statements regarding future events
and future performance of the Company, including statements with respect to
anticipated sales revenue, which involves risks and uncertainties that could
materially affect actual results. Investors should refer to documents that the
Company files from time-to-time with the Securities and Exchange Commission for
a description of certain factors that could cause the actual results to vary
from current expectations and the forward looking statements contained in this
press release. Such filings include, without limitation, the company's Form
10-K, Form 10-Q and Form 8-K reports.
                  
Following are selected LaserSight financial results:

                               THREE MONTHS ENDED
                         (in 000s except per share data)
<TABLE>
<CAPTION>

                                                    March 31, 1999              March 31, 1998
                                                    --------------              --------------


<S>                                                     <C>                         <C>    
Total Revenues                                          $ 4,888                     $ 4,243
Cost of Revenues                                          2,079                       1,263
Gross Profit                                              2,809                       2,980
Research, Development and Regulatory                        781                         818
Selling, General  & Administrative                        5,404                       3,747
Loss from Operations                                     (3,376)                     (1,585)
Other Income (Expense)                                       56                        (311)
Net Loss                                                 (3,320)                     (1,964)
Preferred Stock Accretions / Dividends
    And Conversion Discounts                                 --                      (1,123)
Loss Attributable to Common Shareholders                 (3,320)                     (3,087)
Loss per Common Share - Basic and Diluted                 (0.25)                      (0.30)
Weighted Average Number of Shares Outstanding            13,418                      10,318

SELECTED BALANCE SHEET DATA (in 000s):

                                                    March 31, 1999           December 31, 1998
                                                    --------------           -----------------

Cash and Cash Equivalents                               $10,792                     $  4,438
Accounts and Notes Receivable (Current)                   9,346                        9,418
Total Current Assets                                     30,151                       22,717
Total Current Liabilities                                 8,789                        7,842
Long-Term Obligations                                       832                          560
Stockholders' Equity                                     39,614                       34,015
</TABLE>